Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
Executive Summary
Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.
You may also be interested in...
PDUFA Workload Sets Records, But Inflation Generates More Revenue
The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.
Market Forces May Impact GDUFA III Talks
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.
Generic Industry Market Forces May Impact GDUFA III Talks
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.